Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
39.2M
-
Shares change
-
+6.55M
-
Total reported value, excl. options
-
$1.42B
-
Value change
-
+$242M
-
Put/Call ratio
-
0.23
-
Number of buys
-
102
-
Number of sells
-
-39
-
Price
-
$36.35
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q1 2024
169 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.2M shares
of 42.3M outstanding shares and own 92.64% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.27M shares), Paradigm Biocapital Advisors LP (2.86M shares), BlackRock Inc. (2.65M shares), MORGAN STANLEY (2.4M shares), TANG CAPITAL MANAGEMENT LLC (2.25M shares), Cormorant Asset Management, LP (2.14M shares), COWEN AND COMPANY, LLC (2.12M shares), VANGUARD GROUP INC (1.83M shares), Frazier Life Sciences Management, L.P. (1.79M shares), and JENNISON ASSOCIATES LLC (1.33M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.